Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
10.1016/j.bbrc.2014.06.142 Biochem
Mechanism of Action of Retatrutide (Triple-Target GLP1+GIP+GCGR Agonist) Retatrutide is a new-generation triple co-agonist independently developed by Eli Lilly
Retatrutide's Phase 2 experience follows the class pattern: GI events are the dominant adverse-event category and the burden scales with dose
Monitor your blood sugar regularly to track how quickly levels are changing Maintain consistent healthy eating patterns to avoid glucose spikes Take all diabetes medications exactly as prescribed and at the same times daily Report any episodes of very low blood sugar to your care team promptly Continue other diabetes management strategies including physical activity If you use insulin or a sulfonylurea drug, ask your diabetes doctor about dose adjustments
Retatrutide has a half-life of approximately six days, meaning it takes roughly four to five half-lives, or about 24 to 30 days, to reach steady-state plasma concentrations at any given dose
Any website claiming to sell retatrutide is operating outside of FDA regulations
